全文获取类型
收费全文 | 184397篇 |
免费 | 34976篇 |
国内免费 | 2499篇 |
专业分类
耳鼻咽喉 | 5483篇 |
儿科学 | 6350篇 |
妇产科学 | 3022篇 |
基础医学 | 8307篇 |
口腔科学 | 2105篇 |
临床医学 | 30305篇 |
内科学 | 54525篇 |
皮肤病学 | 8138篇 |
神经病学 | 18338篇 |
特种医学 | 7642篇 |
外国民族医学 | 11篇 |
外科学 | 45665篇 |
综合类 | 660篇 |
现状与发展 | 72篇 |
一般理论 | 30篇 |
预防医学 | 9911篇 |
眼科学 | 4020篇 |
药学 | 3474篇 |
中国医学 | 99篇 |
肿瘤学 | 13715篇 |
出版年
2024年 | 536篇 |
2023年 | 5018篇 |
2022年 | 1640篇 |
2021年 | 3974篇 |
2020年 | 6599篇 |
2019年 | 2988篇 |
2018年 | 8336篇 |
2017年 | 8075篇 |
2016年 | 9264篇 |
2015年 | 9300篇 |
2014年 | 16695篇 |
2013年 | 17137篇 |
2012年 | 7980篇 |
2011年 | 8077篇 |
2010年 | 11789篇 |
2009年 | 15401篇 |
2008年 | 7767篇 |
2007年 | 6152篇 |
2006年 | 8503篇 |
2005年 | 5596篇 |
2004年 | 4763篇 |
2003年 | 3458篇 |
2002年 | 3446篇 |
2001年 | 4367篇 |
2000年 | 3588篇 |
1999年 | 3734篇 |
1998年 | 3956篇 |
1997年 | 3694篇 |
1996年 | 3599篇 |
1995年 | 3408篇 |
1994年 | 2113篇 |
1993年 | 1696篇 |
1992年 | 1683篇 |
1991年 | 1691篇 |
1990年 | 1352篇 |
1989年 | 1409篇 |
1988年 | 1249篇 |
1987年 | 1118篇 |
1986年 | 1160篇 |
1985年 | 971篇 |
1984年 | 760篇 |
1983年 | 689篇 |
1982年 | 629篇 |
1981年 | 516篇 |
1980年 | 472篇 |
1979年 | 539篇 |
1978年 | 486篇 |
1977年 | 531篇 |
1975年 | 394篇 |
1972年 | 420篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
82.
83.
Erythropoietin(EPO) is one of the most successful biopharmaceuticals in history and is used for treating anemia of different origins. However, it became clear that EPO could also work in a neuroprotective, antiapoptotic, antioxidative, angiogenetic and neurotropic way. It causes stimulation of cells to delay cell apoptosis, especially in the central nervous system. In rodent models of focal cerebral ischemia, EPO showed an impressive reduction of infarct size by 30% and improvement of neurobehavioral outcome by nearly 40%. A large animal model dealing with ischemia and reperfusion of the spinal cord showed that EPO could reduce the risk of spinal cord injury significantly. In addition, some clinical studies tested whether EPO works in real live clinical settings. One of the most promising studies showed the innocuousness and improvements in follow-up, outcome scales and in infarct size, of EPO-use in humans suffering from ischemic stroke. Another study ended unfortunately in a negative outcome and an increased overall death rate in the EPO group. The most possible reason was the involvement of patients undergoing simultaneously systemic thrombolysis with recombinant tissue plasminogen activator. An experimental study on rats demonstrated that administration of EPO might exacerbate tissue plasminogen activator-induced brain hemorrhage without reducing the ischemic brain damage. This case shows clearly how useful animal models can be to check negative side effects of a treatment before going into clinical trials. Other groups looked in human trials at the effects of EPO on the outcome after ischemic stroke, relation to circulating endothelial progenitor cells, aneurysmal subarachnoid hemorrhage, traumatic brain injury, hemoglobin transfusion thresholds and elective first-time coronary artery bypass surgery. Most of the results were positive, but are based mostly on small group sizes. However, some of the most neglected facts when focusing on experimental setups of ischemia of the central nervous system are issues like age and comorbidities. It might be extremely worthy to consider these points for future projects, because EPO might influence all these factors. 相似文献
84.
85.
Lara Feulner Hamed S. Najafabadi Simon Tanguay Janusz Rak Yasser Riazalhosseini 《Urologic oncology》2019,37(2):166-175
Background
Clear cell renal cell carcinoma (ccRCC) is known to occur across the adult lifetime traversing the spectrum of age-related organismal changes. Little is known as to how the aging process may affect the course of renal cell carcinoma (RCC) and the repertoire of genes involved.Methods
Using The Cancer Genome Atlas (n?=?436) and Cancer Genomics of the Kidney (n?=?89) datasets, we applied regression analysis to examine associations between patient age and gene expression profiles in ccRCC tumors and normal kidney tissues. Pathway enrichment analysis was performed to identify cellular process that is affected by aging in ccRCC. Moreover, connectivity mapping analysis was used to predict age-dependent response to drug treatments.Results
Our analysis revealed different age-dependent gene expression spectra in ccRCC and normal kidney tissues. These findings were significant and independently reproducible in both datasets examined. Age up-regulated genes, showing higher expression in older patients, were significantly enriched (false discovery rate <0.05) in normal tissues for pathways associated with immune response and extracellular matrix organization, whereas age up-regulated genes in tumors were enriched for metabolism and oxidation pathways. Strikingly, age down-regulated genes in normal cells were also enriched for metabolism and oxidation, while those in tumors were enriched for extracellular matrix organization. Further in silico analysis of potential drug targets predicted preferential efficacy of Phosphoinositide 3-kinase inhibitor or immunotherapy in association with age.Conclusion
We report on previously unrecognized associations between age and molecular underpinnings of RCC, including age-associated expression of genes implicated in RCC development or treatment. 相似文献86.
87.
88.
89.